Abstract-This article describes a prototype microfluidic system for insulin detection and exchanging the results digitally with physicians located off-site. The integrated polydimethysiloxane (PDMS) microfluidic system uses two pneumatic micropumps and one micromixer for chemiluminescent immunoassay, and a developed communications infrastructure for transferring the digital information from the assay site to a remote place for assistance by a trained medical professional. The expert can then directly provide control and diagnosis via the Internet. The insulin detection protocol is based on coupling the highly specific double-antibody sandwich immunoassay with the sensitive chemiluminescence of Luminol-Hydrogen Peroxide (H 2 O 2 ). The peak value of the luminous intensity, recorded automatically by a photometer, is used as an indicator for the insulin concentration of the sample tested. The calibration curves of the insulin measurement were quantified and the insulin detection limit meets the common requirement of current clinical studies of diabetes. The combination of PDMS microfluidic devices and a communication strategy for exchanging information obtained from the assays with off-site diagnosticians offers new opportunities for point-of-care type health monitoring, especially in rural areas where patients must travel great distances to physicians to obtain diagnostic information that might be obtained more cost effectively by local, less-trained personnel.
INTRODUCTION
Microfluidics is a promising technique to replace the conventional diagnostic systems for diabetes screening due to its advantages of low reagent consumption, short analysis time, and multi-process integration [1] [2] [3] . In microfluidic systems, the traditional biochemical processes such as sample pretreatment, reagent transportation, mixing, reaction, separation, detection and product collection can be accomplished automatically on a single chip [4] . The portability characteristic of microfluidic systems, in particular, offers a great opportunity for widespread diabetes screening in the rural environment. Diabetes mellitus (DM) has recently become one of the most prevalent chronic human diseases caused by deficiency or diminished effectiveness of endogenous insulin [5] . Currently, the blood glucose test is the most popular clinical detection for diabetes but irregular blood glucose level, unfortunately, is not a good early indicator for diabetes diagnosis. Previous studies have shown that insulin and connecting peptide (C-peptide) are better suited as early diagnostic immune indicators for the onset of diabetes [6] . The standard test methods for these indicators, which include enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA), are usually based on microplates and large automatic biochemistry analyzers. These methods, while reliable, are extremely ineffective in terms of field testing which is becoming increasingly important for diabetes screening in developing countries where the rise of living standard has also led to an increase in the number of diabetic patients. By comparison, the compact microfluidic systems are more capable of providing fast, point-of-care type medical care for diabetes detection.
Telemedicine provides a fast, efficient, and reliable medium of communication between patients and physicians. Officially, the term is defined as "any transmission of medical information by means of telecommunication technology" [7] . For diabetes, close monitoring of blood insulin and connecting peptide at home is a key component of disease management, but without timely professional feedback, it has somewhat of a lesser value [8] . For those patients living in the rural areas, it is potentially invaluable to have access to their physicians from the comfort of their homes, sparing the time and cost of traveling. Presently, telemedicine is radically changing the healthcare models particularly in the way of healthcare delivery [9] . Its development is assisted tremendously by the development of the Internet which offers a perfect solution for patients to understand the disease information [10] and is allowing them to communicate directly with their physicians. The combination of microfluidic devices and portable detectors capable of transmitting digital information through existing communication channels provides an integrated approach for point-of-care diabetes diagnosis and management [11] .
In the present study, an integrated PDMS-based microfluidic system using the sandwich ELISA detection protocol is developed to measure insulin concentrations. The integrated microfluidic system is composed of two pneumatic micropumps and one micromixer. It automates the process of immunoreactions based on magnetic micro beads. A chemiluminescent detector quantifies the concentration of the insulin captured by the immune beads in the micromixer. The developed microfluidic system can be controlled both locally by a PC and remotely via the Internet, achieving the goal of 
II. EXPERIMENTAL DESIGN
The experimental design consists of three main components: the integrated PDMS-based microfluidic system, the local control circuit, and the Internet-based communication system for telemedicine. Fig. 1 demonstrates the integrated microfluidic system for insulin detection. In addition to two PDMS-based pneumatic micropumps and one micromixer, it also consists of a mini air compressor (HARGRAVES, D730A-23-01, USA) which supplies compressed air to the pneumatic micropumps and micromixer, and a control circuit which produces rectangular wave signals that open and close the electromagnetic valves (EMV) to regulate the air flow (SMC Inc, S070M-5BG-32, Japan) [12] . The air pressure and the EMV frequency are the most critical control parameters of the micropumps and micromixer. An air pressure sensor (OMEGA, DPG1000B-100G, USA) is utilized to monitor the air pressure. Chemiluminescence signals from the micromixer are detected by a photometer (RFL-1A, Remex Co., China). The micromixer is kept in a black box, consequently only light from the micromixing chamber is collected and detected by the photometer. Fig. 2 shows the hardware design of the local control circuit to regulate the EMV frequency. The Samsung S3C2440 embedded processor is a highly integrated chip with ARM920T core. It is equipped with a 16/32-bit RISC microprocessor that is highly suitable for hand-held devices since it can be powered by batteries. Each output of the control circuit can generate independent multi-channel frequencies. Through the liquid crystal display (LCD), the output signals can be viewed together or individually. The power amplifier elevates the signals from the S3C2440 to the level that can drive the EMV. Utilizing WIFI wireless local area network communication, the amplitude and frequency of the EMV control signals can be adjusted through a local PC. This computer is also responsible of data collecting from the insulin measurement and conveying this information to the operator.
A. Integrated PDMS-based Microfluidic System

B. Local Control Circuit and Interface Design
The screen display interface comprises two sections. The upper section produces a live video stream from the camera, which shows both the assay site and the off-site physician. The lower section is a display of the frequency control panel and the measurement results. When the control parameters of the microfluidic system require adjustment, the driving frequencies of the EMV can be regulated easily. 
C. Internet-based communication
The integrated PDMS microfluidic system is connected via a local computer to the Internet for rapid transmission of experimental data to physicians. The photometer provides information of the luminous intensity as the detection initial data to the local computer. Two-way audio and video communication will be established between the tester and expert care providers who can interpret the insulin detection result and recommend corresponding treatment for the patient. Furthermore, both the existing and planned global wireless data communications networks should allow all the bandwidth required to transfer the combination of voice and image data required. The concept comprises the combination and integration of high-end information and communication technologies based on the microfluidic system. 
III. MATERIALS AND METHODS
The magnetic bead based chemiluminescent immunoassay for heterogeneous insulin detection is presented in Fig. 4 . In this procedure, carboxyl-modified magnetic microspheres (Tianjin Baseline ChromTech Research Center, China) are mixed with EDAC (200 mg/ml) to covalently conjunct primary insulin antibodies (Fig. 4a) . Injecting a proper amount of insulin antibody (Shanghai E. Star BioTechnology Co., China.) into the solution, immune magnetic beads are produced (Fig.  4b) . Taking advantage of the specific interaction between the immune beads and insulin (antigen; Shanghai E. Star BioTechnology Co., China.), the insulin molecules are recognized and the semi-sandwich structure is formed (Fig. 4c) . After that, horseradish peroxidase (HRP) labeled insulin antibodies (Shanghai E. Star BioTechnology Co., China.) are added to form the complete sandwich complexes (Fig. 4d) . Through the use of an external magnet, the non-reactive insulin antibodies and antigens are washed away in each step. Without the interfering materials, luminol and hydrogen peroxide (H 2 O 2 ) with the enhancer p-Iodophenol are injected. Under the condition of alkalescence and catalyzed by the HRP of the sandwich complexes, the luminol can be rapidly oxidized by the H 2 O 2 and emits light at a wavelength of ~425nm with an intensity proportional to the amount of the HRP (Fig. 4e) . Since the insulin and its secondary antibody are a one-to-one conjugation, the quantity of HRP connected to the secondary antibody is a direct measurement of the quantity of the insulin. The emitted light is quantified by the photometer.
The immune reaction processes are carried out semiautomatically in the microfluidic system. For the traditional biochemistry analyzers, the mixture of immune magnetic beads and bio-samples should be incubated at 37 0 C for 60 minutes to recognize the target insulin. Following the incubation step, the non-reactive materials are washed manually and the insulin antibodies labeled with HRP are allowed to interact with the target insulin for 30 minutes. Finally, the unbound HRPlabeled insulin antibody is removed by washing. When compared with the conventional insulin detection process, the microfluidic system requires less reagents and shorter reaction time. 
IV. PRIMARY RESULTS AND DISCUSSION
A. Microfluidic System
Two PDMS pneumatic micropumps and one micromixer are connected by Tygon tubings as shown in Fig. 5c . Both the micropump and micromixer consist two thin PDMS layers. In the micropump (Fig. 5a) , the top PDMS layer contains a 100µm-tall microchannel with one inlet and one outlet for fluid transport while the bottom PDMS layer consists of three membrane-enclosed air chambers. The three serially-connected air chambers have different volumes. In the micromixer (Fig.  5b) , there is a fluid mixing chamber (2mm diameter and 100µm depth) with two inlets and one outlet in the top PDMS layer. Six air chambers are connected in series to each other through serpentine microchannels in the bottom PDMS layer.
The working principles of the pneumatic micropump and micromixer are similar. Air pulses produced by the EMV deflect the diaphragms of the air chambers in a sequential manner causing either fluid flow in the micropump or mixing in the micromixer. The flow rate of the micropump and the mixing efficiency of the micromixer are controlled by the actuation pressure and frequency. Fig. 6 demonstrates the variation of chemiluminescent light intensity (RLU) with time during the chemiluminescence reaction process in the micromixer. The relationship is parabolic in nature and it takes about 1 minute for the light intensity to reach its peak value. The peak value is used here to represent the concentration of HRP in the reaction, which is equivalent to the insulin concentration of each curve. To detect the insulin concentration automatically, the time-varying luminous intensity is digitized and the result is further
B. Automatic Detection of Insulin Concentration
processed to determine the peak value directly. Instead of the complete light-intensity curve, only information related to the insulin concentration is shown on the screen of both the local and the remote computer. 
C. Insulin Sensitivity and Calibration
The immunoreactions are accomplished semi-automatically in the integrated microfluidic system as shown in Fig. 5 . Following each immune reaction, washing procedures are carried out with the help of a permanent magnet which is fixed to the outer surface of the mixing chamber. The micromixer used for the chemiluminesce based measurement of insulin antigen between the immune beads and HRP labeled antibodies is placed in the dark box of the photometer to reduce noise and improve sensitivity. The mixer is operated at the optimal working parameters. The solution which contains the HRP labeled insulin sandwich complex, the hydrogen peroxide (7.5×10 -3 M), and the enhancer p-Iodophenol (3mg/ml) is injected into the mixing chamber via one inlet of the Y-shaped microchannel, while another inlet is used to inject the luminol solution (7.8×10 -3 M). The two solutions are fed into the mixing chamber simultaneously, and allowed to achieve complete reaction (Fig. 4e) . The concentrations of the chemicals used for this chemiluminescencent measurement were optimized in advance. Fig. 7 shows the calibration curve of the insulin immunoassay, demonstrating the relationship between the chemiluminescence signal and the insulin concentration. As indicated by the figure, the insulin detection limit of the microfluidic system is about 4×10 -10 M which generally meets the present clinical requirements. The insulin concentration forms a relatively linear relationship with the chemiluminescent light intensity. The total reaction time of the microfluidic system is about 10 minutes as compared to the traditional method of about 120 minutes. 
V. CONCLUSIONS
The present paper describes a PDMS microfluidic system for insulin measurement by combining chemiluminescent immunoassays with Cyber-based telemedicine. This technology provides the perspective to advance primary healthcare by supporting diagnostics and monitoring of insulin status for DM. Through the Internet for data and image transmission, the real-time communication purposes are achieved, offering an integrated approach for detection and diagnosing disease in locations that are difficult to access by trained physicians. The insulin detection limit of the microfluidic system is 4×10 -10 M which meets the common requirement of current clinical studies of diabetes. The reaction time of the immunoreactions in the microfluidic system is about 10 minutes which is more than ten times faster than that of the traditional methods. Further studies are currently being carried out to validate these designs and to promote telemedicine as an opportunity to better diabetic patient care. The principle that is being investigated and prepared for clinical routine can be adapted to other pathologies and bring progress in terms of early detection.
